Q217 earnings coming in tomorrow @ $1.39 Revenue grows 7% YIKES Stocks down, may be time to dump @ $72
I think $75 was it. All the positive news coming out and Abbv is declining. This is the first signal of the impending Humira loss and the street is already factoring in 2020 which looms over Abbvies head like a big sledge hammer. The ride is about to be over and Rick will walk with $50M.
With Abbv at $77, Abt at $51and Gild at $82 my investments returned gains of $1.7M since Q416. Vanguard Portfolio at $15.2M. Love Abbott Labs and Uncle Miles !!
Besides the positive ABT-494 data, AbbVie won the IPR review against Coherus. No IPR review of the 619 in all four challenges. CHRS is DOWN 6.42% and ABBV is UP 6.20% on this news. Rick said we would vigorously fight all challenges and he wasn't lying.